Mn Services Vermogensbeheer B.V. Sells 4,600 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Mn Services Vermogensbeheer B.V. reduced its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161,000 shares of the company’s stock after selling 4,600 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in GE HealthCare Technologies were worth $12,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Pathway Financial Advisers LLC bought a new position in shares of GE HealthCare Technologies during the 1st quarter valued at about $25,000. BNP Paribas bought a new position in GE HealthCare Technologies during the first quarter valued at approximately $30,000. Sachetta LLC purchased a new position in GE HealthCare Technologies during the 4th quarter valued at approximately $31,000. Rise Advisors LLC increased its stake in GE HealthCare Technologies by 241.4% in the 1st quarter. Rise Advisors LLC now owns 338 shares of the company’s stock worth $31,000 after acquiring an additional 239 shares during the last quarter. Finally, Riverview Trust Co purchased a new stake in shares of GE HealthCare Technologies during the 1st quarter worth approximately $31,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GEHC has been the subject of a number of analyst reports. Stifel Nicolaus began coverage on shares of GE HealthCare Technologies in a report on Tuesday, August 6th. They issued a “buy” rating and a $100.00 price target for the company. Bank of America dropped their target price on GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a report on Wednesday, May 1st. Redburn Atlantic upgraded GE HealthCare Technologies to a “strong-buy” rating in a report on Thursday, August 1st. The Goldman Sachs Group started coverage on shares of GE HealthCare Technologies in a research note on Thursday, May 30th. They issued a “neutral” rating and a $87.00 target price on the stock. Finally, Mizuho dropped their price target on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.00.

Insider Buying and Selling

In other GE HealthCare Technologies news, CTO Taha Kass-Hout sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total transaction of $259,710.00. Following the transaction, the chief technology officer now owns 67,300 shares of the company’s stock, valued at approximately $5,296,510. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Thomas J. Westrick sold 2,750 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $80.78, for a total transaction of $222,145.00. Following the completion of the sale, the chief executive officer now directly owns 17,509 shares in the company, valued at approximately $1,414,377.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Taha Kass-Hout sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the sale, the chief technology officer now directly owns 67,300 shares in the company, valued at approximately $5,296,510. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

GE HealthCare Technologies Trading Up 0.5 %

GEHC stock traded up $0.41 during mid-day trading on Friday, reaching $84.78. The company had a trading volume of 1,511,760 shares, compared to its average volume of 3,015,838. The company has a market capitalization of $38.70 billion, a PE ratio of 24.79, a price-to-earnings-growth ratio of 3.00 and a beta of 1.17. The firm has a 50 day moving average of $80.77 and a 200 day moving average of $83.41. GE HealthCare Technologies Inc. has a 12 month low of $62.35 and a 12 month high of $94.50. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.06 and a quick ratio of 0.83.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.02. The company had revenue of $4.84 billion for the quarter, compared to analysts’ expectations of $4.88 billion. GE HealthCare Technologies had a return on equity of 25.26% and a net margin of 8.10%. GE HealthCare Technologies’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.92 earnings per share. On average, equities analysts predict that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Friday, July 19th were issued a $0.03 dividend. The ex-dividend date was Friday, July 19th. This represents a $0.12 annualized dividend and a dividend yield of 0.14%. GE HealthCare Technologies’s payout ratio is currently 3.51%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.